Rubicon Research Limited has informed the Exchange regarding a press release dated April 15, 2026, titled "Press Release".
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts more than Nifty Microcap 250 and 5.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Rubicon Research Limited has acquired 85% equity ownership in Arinna Lifesciences Limited, a domestic formulations company focused on the central nervous system (CNS) therapeutic category. Arinna brings a portfolio of over 60 brands, a network of 4,000+ prescribers, and an established distribution network across India. The transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt free basis, with the purchase consideration for the 85% stake at approximately INR 175.92 Crores (INR 158.53 per share). For the 9 months ended December 2025, Arinna reported provisional revenue of INR 56.7 Crores and EBITDA of INR 9.5 Crores. The transaction is expected to close within 30 days, with Arinna's founder retaining a 15% stake and continuing as Managing Director.
The acquisition gives Rubicon a launchpad to deploy its CNS-focused playbook in the Indian domestic formulations market, expanding from its US-centric operations into the India market. It strengthens Rubicon's chronic products portfolio and provides access to a wide prescriber and distribution network.